



Biotech Daily

Monday January 3, 2022

Special Edition

2021: BDI-40 UP 23%; BIG CAPS UP 14% ASX200 UP 13%; NBI DOWN 1%

Actinogen Up 847%, Imugene 387%, Prescient 249%; Oncosil Down 63%, Polynovo 61%

The Biotech Daily Top-40 Index (BDI-40) climbed 0.1 percent in December to close the year up 22.7 percent to a collective market capitalization of \$22,522 million.

The benchmark S&P ASX200 was up 2.6 percent for December and 13.0 percent for the year, the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped 0.1 percent in December but were up 14.3 percent the year, while in the US, the Nasdaq Biotechnology Index (NBI) closed 2021 down 0.6 percent.

Resmed ended the year up 32.0 percent at \$52,309 million, Cochlear climbed 15.9 percent to \$14,405 million, with CSL up 8.7 percent to \$140,034 million.

Twenty of the BDI-40 stocks were up in 2021, with 19 up more than 10 percent and seven up by more than 100 percent; while 20 fell, with 19 down more than 10 percent and three down by more than 50 percent.

It was a tale of two indices - with the BDI-20 boasting just six rises and 14 falls, while the Second 20 was the reverse with 14 rises and six falls.

Actinogen was the best of the BDI-40 in 2021, up 846.7 percent to \$284 million, from a low base of \$30 million.


Imugene felt the impact of gravity in December falling \$833 million or 26.5 percent for the month, but still coming second for the year up 386.5 percent to \$2,306 million. The fall was mostly offset by Nanosonics and Telix climbing more than \$280 million each in December. Imugene was followed up for the year by Prescient (248.8%), Neuren (223.1%), Impedimed (130.4%), Universal Biosensors (128.6%), Telix (104.2%), Pro Medicus (84.5%), Patrys (76.7%), Optiscan (76.2%) and Antisense (73.3%).

Oncosil led the falls, down 63.3 percent to \$36 million, followed by Polynovo (60.9%), Osprey (55.6%), Resonance (39.3%), Mesoblast (33.3%), Volpara (27.2%), Opthea (26.1%), Compumedics (25.8%), Paradigm (25.2%) and Cyclopharm (23.9%).


Cannabis Corner edged up 1.6 percent in December, driven by Cronos and Incannex offsetting falls by 14 of the 22 companies, but up 18.9 percent from a low end to 2020.

On the Nasdaq, Eyepoint (formerly Psivida) climbed 342.6 percent to \$571 million and Queensland's Protagonist ended the year up 99.6 percent at \$2,247 million, while Israel's Redhill, with Australian assets, fell 53.7 percent to \$183 million.


BDI-40 v ASX200 Jun 30, 2006 to Dec 31, 2021- Adjusted



Big Caps \$m (Cochlear, CSL, Resmed) Dec 31, 2016 – Dec 31, 2021



BDI-40 (\$m) v S&P ASX 200 – Dec 31, 2019 – Dec 31, 2021 (current, raw data)



Biotech Daily Top 40 with Market Capitalization At December 31, 2021

Company \$Am	Jan-21	Dec-21	Jan-22
Cochlear	12,425	14,326	14,405
CSL	128,840	139,795	140,034
Resmed	39,622	52,860	52,309
BDI-20			
Avita	530	485	426
Clinuvel	1,103	1,422	1,412
Compumedics	89	60	66
Cyclopharm	201	169	153
Cynata	95	75	78
Ellex	51	47	47
Genetic Signatures	287	188	256
Immutep	269	406	419
Medical Developments	464	343	356
Mesoblast	1,322	1,103	882
Nanosonics	2,417	1,647	1,934
Neuren	147	227	475
Opthea	648	420	479
Paradigm	576	478	431
Pharmaxis	37	52	66
Polynovo	2,565	966	1,002
Pro Medicus	3,560	6,522	6,569
Starpharma	635	441	525
Telix	1,060	1,881	2,164
Volpara	360	287	262
Second 20			
Actinogen	30	229	284
Alterity	63	60	51
Amplia	26	27	32
Antisense	75	135	130
Dimerix	47	79	79
Impedimed	135	302	311
Imugene	474	3,139	2,306
Kazia	146	187	166
LBT Innovations	35	27	33
Next Science	243	245	246
Oncosil	98	36	36
Optiscan	63	114	111
Orthocell	83	100	101
Osprey	36	19	16
Patrys	43	74	76
Prescient	43	156	150
Proteomics	83	126	128
Resonance	107	48	65
Universal Biosensors	77	157	176
Uscom	25	16	23

* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix, Volpara and non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: <https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily